NCT00381472 is a Phase 3 clinical trial of Ropinirole in Parkinson Disease, sponsored by GlaxoSmithKline.

Who is sponsoring NCT00381472?

NCT00381472 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT00381472?

Interventions in NCT00381472: Ropinirole.

What condition does NCT00381472 study?

NCT00381472 studies Parkinson Disease.

Is NCT00381472 still recruiting?

NCT00381472 is currently completed. Last updated 21 March 2017.

Last reviewed 2017-03-21 · How we verify

NCT00381472

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole CR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-dopa

Completed Phase 3 Last updated 21 March 2017

What this trial tests

Phase 3 trial testing Ropinirole in Parkinson Disease in 393 participants. Completed in 1 December 2004.

Timeline

1 June 2003

1 December 2004

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	393
Start date	1 June 2003
Estimated completion	1 December 2004
Sites	76 locations across United States, Belgium, Czechia, France, Germany, Hungary, Italy, Poland

Drugs / interventions tested

Ropinirole (ropinirole) — full drug profile →

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

30 and older, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Mean change from baseline in awake time "off" at Week 24 LOCF (last observation carried forward).

Sponsor's own description

The purpose of this double-blind, placebo controlled study is to evaluate the safety and effectiveness of an investigational Parkinson's disease drug in patients with advanced disease who are not well-controlled on their L-dopa medication.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Sleep Duration and "on" Time during Different Periods of the Day and Night in Patients with Advanced Parkinson's Disease Receiving Adjunctive Ropinirole Prolonged Release.
Reichmann H, Cooper J, Rolfe K, Martinez-Martin P. · · 2011 · cited 7× · PMID 21687750 · DOI 10.4061/2011/354760

Verify or expand the search:

Other trials of Ropinirole

Trials testing the same drug.

NCT03806530 — DIalysis Symptom COntrol-Restless Legs Syndrome Trial · Phase 3 · completed
NCT03708237 — Effectiveness of Ropinirole and Gabapentin for the Treatment of RLS in Patients on Maintenance HD · Phase 2 · terminated
NCT03038308 — Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole · Phase 1, PHASE2 · completed
NCT03176966 — Ropinirole for the Treatment of Muscle Cramps in Patients With Cirrhosis · Phase 4 · completed
NCT01435915 — Ropinirole PR Pharmacokinetics Study Among Chinese Healthy Subjects · Phase 1 · completed

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00381472 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 21 March 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00381472.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing